<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157234</url>
  </required_header>
  <id_info>
    <org_study_id>BYS-MD-42</org_study_id>
    <nct_id>NCT01157234</nct_id>
  </id_info>
  <brief_title>Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients</brief_title>
  <official_title>Nebivolol Effect on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the blood pressure lowering efficacy of nebivolol among renal
      transplant recipients who are on calcineurin inhibitors which are believed to contribute to
      hypertension by sympathetic nervous system (SNS) activation and decreased prostaglandin and
      nitric oxide production. Hypotheses:

        1. There is a significant difference in the effect of 12 months of Nebivolol versus
           Metoprolol treatment on the plasma nitric oxide level of hypertensive renal transplant
           patients.

        2. There is a significant difference in the effect of 12 months of Nebivolol versus
           Metoprolol treatment on the estimated glomerular filtration rate of hypertensive renal
           transplant patients.

        3. There is a significant difference in the effect of 12 months of Nebivolol versus
           Metoprolol treatment on the systolic, diastolic and mean arterial blood pressures of
           hypertensive renal transplant patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nitric Oxide (NO) plays a plethora of functions in the kidney including vascular and
      hemodynamic regulation, fluid and electrolyte transport, and is an important component of
      pressure natriuresis and tubule-glomerular feedback.

      Deficient NO levels have been associated with oxidative stress in conditions like
      hypertension, diabetes mellitus, and cardiovascular disease. NO deficiency has been
      identified in states of chronic progressive renal disease and altered NO production and/or
      decreased bioavailability is believed to characterize the endothelial dysfunction and
      resistant hypertension of renal failure.

      It has been shown that kidney transplantation improves endothelium-dependent vasodilation in
      patients with end-stage renal disease (ESRD) and the NO activity significantly increases
      after transplantation. However, calcineurin inhibitor drugs used in the anti-rejection
      regimen can reduce endothelial NO production and aggravate hypertension through vascular and
      renal mechanisms. In turn, uncontrolled elevation in blood pressure has been associated with
      increased renal allograft failure and post-transplant mortality.

      In the absence of randomized clinical trials of antihypertensive drugs and optimal blood
      pressure goals in kidney transplant recipients. There is no scientifically-robust consensus
      on the specific drugs to use among transplant patients. Nebivolol, is a third generation
      B1-selective B-blocker shown to have similar BP-lowering effect as other B-blockers,
      angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blocker (ARB)
      drugs, and calcium channel blockers. Nebivolol ameliorates hypertension by increasing NO
      release, promoting arterial and venous vasodilatation and beta-blockade. Nebivolol has
      beneficial effect on the kidney allograft. Studies in animal transplants have shown that
      nebivolol could reduce ischemia-induced reperfusion injury, alleviate renal perfusion
      pressure and increase NO release with associated vasodilation of the renal vasculature. These
      effects have not been seen with older generation B-blockers like propranolol or bisoprolol.
      Finally, in surgically reduced renal mass, nebivolol has been demonstrated to attenuate
      collagen type 1 expression with lessening of glomerular and interstitial fibrosis.

      In this study, the effect of nebivolol and metoprolol on the change in NO level at baseline
      and at the 12th month of treatment will be compared. Similarly,the effects of the two drugs
      on the change in renal function, blood pressure, and blood pressure regimen from baseline to
      month-12 of treatment will also be compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Nitric Oxide Level Change From Baseline to Month 12 Between the Groups.</measure>
    <time_frame>Change in Baseline, Month-12</time_frame>
    <description>Percent change in Nitric Oxide (NO) blood level (nmol/L)=[Month-12 NO blood level minus baseline NO blood level] divided by [baseline NO blood level] multiplied by 100, where all levels are in nmol/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated Glomerular Filtration Rate (ml/Minute) Change From Baseline to Month-12 Between the Groups</measure>
    <time_frame>Change in Baseline, Month-12</time_frame>
    <description>The changed percentage in Estimated Glomerular Filtration Rate (eGFR), (based on the Modification of Diet in Renal Disease Equation)=[Month-12 GFR level minus baseline eGFR level] divided by [baseline eGFR level] multiplied by 100, where all levels are in ml/min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 of Treatment Between the Groups</measure>
    <time_frame>Change in Baseline, Month-12</time_frame>
    <description>Absolute change in Systolic Blood Pressure (SBP), (millimeter, Mercury)=Month-12 sitting trough SBP level minus baseline sitting trough SBP level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups</measure>
    <time_frame>Change in Baseline, Month-12</time_frame>
    <description>Absolute Change in Diastolic Blood Pressure (DBP), (millimeter, Mercury)= Month-12 sitting trough Diastolic Blood Pressure (millimeter, Mercury) level minus baseline sitting trough Diastolic Blood Pressure (millimeter, Mercury).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups</measure>
    <time_frame>Change in Baseline, Month-12</time_frame>
    <description>Absolute change in Mean Arterial Blood Pressure, (MAP), (millimeter, Mercury= Month-12 sitting trough MAP minus baseline sitting trough MAP.
Mean Arterial Pressure= 2/3 trough diastolic blood pressure + 1/3 trough systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Antihypertensive Drug Classes Change From Baseline to Month-12 Between the Groups.</measure>
    <time_frame>Change in Baseline, Month-12</time_frame>
    <description>Percent change in quantity of Anti-Hypertensive Drug Classes (AHDC)=[Month-12 absolute number of AHDC minus baseline absolute number of AHDC] divided by [baseline absolute number of AHDC] multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Asymmetric Dimethylarginine (ADMA) Change From Baseline to Month 12 Between the Groups</measure>
    <time_frame>Baseline, Month-12</time_frame>
    <description>Percent change in plasma ADMA (umol/L)=[month-12 plasma ADMA level minus baseline plasma ADMA level] divided by [baseline plasma ADMA level] multiplied by 100, where all levels are in umol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Arginine (ARG) Level Change From Baseline to Month-12 Between Groups</measure>
    <time_frame>Baseline, Month-12</time_frame>
    <description>Percent change in plasma Arginine (umol/L)=[month-12 plasma Arginine level minus baseline plasma Arginine level] divided by [baseline plasma Arginine level] multiplied by 100, where all levels are in umol/L</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma Nitric Oxide Level (Nmol/L) at Month-12 Between the Groups.</measure>
    <time_frame>12 Months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>Nebivolol 5 mg once daily, titrated to a maximum total daily dose of 40 mg to achieve a blood pressure of &lt; 140/ 90.</description>
    <arm_group_label>Nebivolol</arm_group_label>
    <other_name>Bystolic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Metoprolol 25 mg twice daily, titrated to a maximum total daily dose of 400 mg to achieve a blood pressure &lt; 140/90.</description>
    <arm_group_label>Metoprolol</arm_group_label>
    <other_name>Lopressor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women at least 18 years of age who are recipients of - a solitary kidney or
             combined kidney-pancreas transplant within the last twenty four months

          -  Current diagnosis of hypertension

          -  Normal hepatic enzymes

          -  Estimated creatinine clearance (by cockcroft-gault formula) &gt;or= 30 ml/min

        Exclusion Criteria:

          -  Any contraindication to taking beta-blockers, specifically Nebivolol or Metoprolol.
             Conditions such as : (bradycardia heart rate (HR) &lt;60 beats per minute , heart block &gt;
             1st degree, decompensated cardiac failure, sick sinus syndrome (unless permanent
             pacemaker in place), severe hepatic impairment( defined as elevation of aspartamine
             aminotransferase , alanine aminotransferase, or bilirubin levels to three times upper
             limit of normal reference range), severe peripheral arterial circulatory disorder,
             history of bronchospasm and /or asthma and /or regular medication with inhaled
             bronchodilators. or , or any medical condition that in the opinion of the investigator
             may interfere with the subject's ability to successfully complete the protocol.

          -  Any medical condition which, in the opinion of the Principal Investigator, might
             compromise the safety of the subject in participating in the protocol such as
             hypotension or not requiring antihypertensive medications.

          -  Any serious systemic disease that might complicate management and reduce life
             expectancy.

          -  Uncontrolled hypertension defined as systolic blood pressure (SBP) &gt; 210 or diastolic
             blood pressure (DBP) &gt; 120 mm Hg.

          -  Symptomatic hypotension

          -  Previous intolerance to beta blockers

          -  Cerebrovascular accident within 3 months of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfonso Santos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schmidt RJ, Yokota S, Tracy TS, Sorkin MI, Baylis C. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am J Physiol. 1999 May;276(5 Pt 2):F794-7.</citation>
    <PMID>10330062</PMID>
  </reference>
  <reference>
    <citation>Uzun H, Konukoglu D, Besler M, Erdenen F, Sezgin C, Muderrisoglu C. The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels. Clin Invest Med. 2008;31(1):E1-7.</citation>
    <PMID>18312743</PMID>
  </reference>
  <reference>
    <citation>Passauer J, Büssemaker E, Lassig G, Gross P. Kidney transplantation improves endothelium-dependent vasodilation in patients with endstage renal disease. Transplantation. 2003 Jun 15;75(11):1907-10.</citation>
    <PMID>12811255</PMID>
  </reference>
  <reference>
    <citation>Zhang W, Zhou C, Xie J, Chen B, Chang L. Serum asymmetric dimethylarginine and endothelial function after renal transplantation. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009 Apr;34(4):289-94.</citation>
    <PMID>19411743</PMID>
  </reference>
  <reference>
    <citation>Schwenger V, Zeier M, Ritz E. Hypertension after renal transplantation. Ann Transplant. 2001;6(4):25-30. Review.</citation>
    <PMID>12035455</PMID>
  </reference>
  <reference>
    <citation>Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int. 1998 Jan;53(1):217-22.</citation>
    <PMID>9453022</PMID>
  </reference>
  <reference>
    <citation>Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med. 1988 Aug;85(2):134-8.</citation>
    <PMID>3041828</PMID>
  </reference>
  <reference>
    <citation>Koomans HA, Ligtenberg G. Mechanisms and consequences of arterial hypertension after renal transplantation. Transplantation. 2001 Sep 27;72(6 Suppl):S9-12. Review.</citation>
    <PMID>11585243</PMID>
  </reference>
  <reference>
    <citation>Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006 Sep 15;82(5):603-11. Review.</citation>
    <PMID>16969281</PMID>
  </reference>
  <reference>
    <citation>Cheng JW. Nebivolol: a third-generation beta-blocker for hypertension. Clin Ther. 2009 Mar;31(3):447-62. doi: 10.1016/j.clinthera.2009.03.007. Review.</citation>
    <PMID>19393838</PMID>
  </reference>
  <reference>
    <citation>Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl. 2004 Oct;1:2-16. Review.</citation>
    <PMID>15587107</PMID>
  </reference>
  <reference>
    <citation>Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003 Aug 1;92(3):344-8.</citation>
    <PMID>12888152</PMID>
  </reference>
  <reference>
    <citation>Brehm BR, Wolf SC, Bertsch D, Klaussner M, Wesselborg S, Schüler S, Schulze-Osthoff K. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res. 2001 Feb 1;49(2):430-9.</citation>
    <PMID>11164853</PMID>
  </reference>
  <reference>
    <citation>Gandhi C, Zalawadia R, Balaraman R. Nebivolol reduces experimentally induced warm renal ischemia reperfusion injury in rats. Ren Fail. 2008;30(9):921-30. doi: 10.1080/08860220802353900.</citation>
    <PMID>18925533</PMID>
  </reference>
  <reference>
    <citation>Georgescu A, Pluteanu F, Flonta ML, Badila E, Dorobantu M, Popov D. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol. 2005 Jan 31;508(1-3):159-66. Epub 2005 Jan 7.</citation>
    <PMID>15680267</PMID>
  </reference>
  <reference>
    <citation>Kakoki M, Hirata Y, Hayakawa H, Nishimatsu H, Suzuki Y, Nagata D, Suzuki E, Kikuchi K, Nagano T, Omata M. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension. 1999 Jan;33(1 Pt 2):467-71.</citation>
    <PMID>9931149</PMID>
  </reference>
  <reference>
    <citation>Pires MJ, Rodríguez-Peña AB, Arévalo M, Cenador B, Evangelista S, Esteller A, Sánchez-Rodríguez A, Colaço A, López-Novoa JM. Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction. J Hypertens. 2007 Dec;25(12):2486-96.</citation>
    <PMID>17984671</PMID>
  </reference>
  <reference>
    <citation>Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004 Aug;4(8):1289-95.</citation>
    <PMID>15268730</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2010</study_first_submitted>
  <study_first_submitted_qc>July 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 5, 2010</study_first_posted>
  <results_first_submitted>January 25, 2016</results_first_submitted>
  <results_first_submitted_qc>February 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2016</results_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Kidney transplantation</keyword>
  <keyword>Renal function</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>Nebivolol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at the University of Florida and Shands Renal Transplant Clinic.
The first patient was randomized on July 8, 2010 and the follow up of the last patient ended on July 21, 2014.</recruitment_details>
      <pre_assignment_details>32 participants were screened, 2 failed screening and 30 met the eligibility criteria and randomized to either the arm with nebivolol or the arm with metoprolol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nebivolol</title>
          <description>Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
        </group>
        <group group_id="P2">
          <title>Metoprolol</title>
          <description>Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set included all participants who signed informed consent and received at least one dose of study drug</population>
      <group_list>
        <group group_id="B1">
          <title>Nebivolol</title>
          <description>Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
        </group>
        <group group_id="B2">
          <title>Metoprolol</title>
          <description>Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="15.9"/>
                    <measurement group_id="B2" value="46.4" spread="13.8"/>
                    <measurement group_id="B3" value="49.7" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma Nitric Oxide</title>
          <description>Full analysis included all participants who signed informed consent and received at least one dose of study drug.</description>
          <units>nmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.93" spread="21.09"/>
                    <measurement group_id="B2" value="48.23" spread="15.37"/>
                    <measurement group_id="B3" value="50.53" spread="17.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated Glomerular Filtration Rate</title>
          <description>Estimated glomerular filtration rate is calculated according to the modification of diet in renal disease equation using age, gender and race in calculating kidney function.
Full analysis included all participants who signed informed consent and received at least one dose of study drug</description>
          <units>milliliter/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.13" spread="14.15"/>
                    <measurement group_id="B2" value="54.47" spread="14.65"/>
                    <measurement group_id="B3" value="53.80" spread="13.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Full analysis included all participants who signed informed consent and received at least one dose of study drug.</description>
          <units>millimeter, mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132.93" spread="15.79"/>
                    <measurement group_id="B2" value="131.33" spread="18.14"/>
                    <measurement group_id="B3" value="132.13" spread="16.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>Full analysis included all participants who signed informed consent and received at least one dose of study drug</description>
          <units>millimeter, mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.07" spread="8.59"/>
                    <measurement group_id="B2" value="86.33" spread="8.62"/>
                    <measurement group_id="B3" value="85.20" spread="8.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Arterial Blood Pressure</title>
          <description>Full analysis included all participants who signed informed consent and received at least one dose of study drug</description>
          <units>millimeter, mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100.20" spread="8.06"/>
                    <measurement group_id="B2" value="101.47" spread="10.76"/>
                    <measurement group_id="B3" value="100.83" spread="9.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Antihypertensive Drug Classes Being Used</title>
          <description>Full analysis included all participants who signed informed consent and received at least one dose of study drug</description>
          <units>Antihypertensive Drug Classes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.00" spread="0.84"/>
                    <measurement group_id="B2" value="1.80" spread="0.68"/>
                    <measurement group_id="B3" value="1.90" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Nitric Oxide Level Change From Baseline to Month 12 Between the Groups.</title>
        <description>Percent change in Nitric Oxide (NO) blood level (nmol/L)=[Month-12 NO blood level minus baseline NO blood level] divided by [baseline NO blood level] multiplied by 100, where all levels are in nmol/L.</description>
        <time_frame>Change in Baseline, Month-12</time_frame>
        <population>Full analysis set included all participants who signed informed consent and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Nitric Oxide Level Change From Baseline to Month 12 Between the Groups.</title>
          <description>Percent change in Nitric Oxide (NO) blood level (nmol/L)=[Month-12 NO blood level minus baseline NO blood level] divided by [baseline NO blood level] multiplied by 100, where all levels are in nmol/L.</description>
          <population>Full analysis set included all participants who signed informed consent and received at least one dose of study drug.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.47" spread="9.20"/>
                    <measurement group_id="O2" value="-17.27" spread="9.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>28.73</param_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.93</ci_lower_limit>
            <ci_upper_limit>55.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Glomerular Filtration Rate (ml/Minute) Change From Baseline to Month-12 Between the Groups</title>
        <description>The changed percentage in Estimated Glomerular Filtration Rate (eGFR), (based on the Modification of Diet in Renal Disease Equation)=[Month-12 GFR level minus baseline eGFR level] divided by [baseline eGFR level] multiplied by 100, where all levels are in ml/min.</description>
        <time_frame>Change in Baseline, Month-12</time_frame>
        <population>Full analysis set included all participants who signed inform consent and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Glomerular Filtration Rate (ml/Minute) Change From Baseline to Month-12 Between the Groups</title>
          <description>The changed percentage in Estimated Glomerular Filtration Rate (eGFR), (based on the Modification of Diet in Renal Disease Equation)=[Month-12 GFR level minus baseline eGFR level] divided by [baseline eGFR level] multiplied by 100, where all levels are in ml/min.</description>
          <population>Full analysis set included all participants who signed inform consent and received at least one dose of study drug.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16" spread="7.16"/>
                    <measurement group_id="O2" value="10.43" spread="7.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>8.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.58</ci_lower_limit>
            <ci_upper_limit>29.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 of Treatment Between the Groups</title>
        <description>Absolute change in Systolic Blood Pressure (SBP), (millimeter, Mercury)=Month-12 sitting trough SBP level minus baseline sitting trough SBP level</description>
        <time_frame>Change in Baseline, Month-12</time_frame>
        <population>Full analysis set included all participants who signed inform consent and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 of Treatment Between the Groups</title>
          <description>Absolute change in Systolic Blood Pressure (SBP), (millimeter, Mercury)=Month-12 sitting trough SBP level minus baseline sitting trough SBP level</description>
          <population>Full analysis set included all participants who signed inform consent and received at least one dose of study drug.</population>
          <units>millimeter, Mercury</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.65" spread="2.73"/>
                    <measurement group_id="O2" value="-3.88" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least squares mean difference</param_type>
            <param_value>1.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.74</ci_lower_limit>
            <ci_upper_limit>9.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups</title>
        <description>Absolute Change in Diastolic Blood Pressure (DBP), (millimeter, Mercury)= Month-12 sitting trough Diastolic Blood Pressure (millimeter, Mercury) level minus baseline sitting trough Diastolic Blood Pressure (millimeter, Mercury).</description>
        <time_frame>Change in Baseline, Month-12</time_frame>
        <population>Full analysis set included all participants who signed inform consent and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups</title>
          <description>Absolute Change in Diastolic Blood Pressure (DBP), (millimeter, Mercury)= Month-12 sitting trough Diastolic Blood Pressure (millimeter, Mercury) level minus baseline sitting trough Diastolic Blood Pressure (millimeter, Mercury).</description>
          <population>Full analysis set included all participants who signed inform consent and received at least one dose of study drug.</population>
          <units>millimeter, mercury</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="1.91"/>
                    <measurement group_id="O2" value="-2.35" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Arterial Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups</title>
        <description>Absolute change in Mean Arterial Blood Pressure, (MAP), (millimeter, Mercury= Month-12 sitting trough MAP minus baseline sitting trough MAP.
Mean Arterial Pressure= 2/3 trough diastolic blood pressure + 1/3 trough systolic blood pressure</description>
        <time_frame>Change in Baseline, Month-12</time_frame>
        <population>Full analysis set included all participants who signed inform consent and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial Blood Pressure (Millimeter, Mercury) Change From Baseline to Month-12 Between the Groups</title>
          <description>Absolute change in Mean Arterial Blood Pressure, (MAP), (millimeter, Mercury= Month-12 sitting trough MAP minus baseline sitting trough MAP.
Mean Arterial Pressure= 2/3 trough diastolic blood pressure + 1/3 trough systolic blood pressure</description>
          <population>Full analysis set included all participants who signed inform consent and received at least one dose of study drug.</population>
          <units>millimeter, Mercury</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="2.11"/>
                    <measurement group_id="O2" value="-3.19" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Antihypertensive Drug Classes Change From Baseline to Month-12 Between the Groups.</title>
        <description>Percent change in quantity of Anti-Hypertensive Drug Classes (AHDC)=[Month-12 absolute number of AHDC minus baseline absolute number of AHDC] divided by [baseline absolute number of AHDC] multiplied by 100.</description>
        <time_frame>Change in Baseline, Month-12</time_frame>
        <population>Percent change</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Antihypertensive Drug Classes Change From Baseline to Month-12 Between the Groups.</title>
          <description>Percent change in quantity of Anti-Hypertensive Drug Classes (AHDC)=[Month-12 absolute number of AHDC minus baseline absolute number of AHDC] divided by [baseline absolute number of AHDC] multiplied by 100.</description>
          <population>Percent change</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.14" spread="11.58"/>
                    <measurement group_id="O2" value="8.70" spread="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Plasma Nitric Oxide Level (Nmol/L) at Month-12 Between the Groups.</title>
        <time_frame>12 Months</time_frame>
        <population>Full analysis set included all participants who signed inform consent and received at least one dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Nitric Oxide Level (Nmol/L) at Month-12 Between the Groups.</title>
          <population>Full analysis set included all participants who signed inform consent and received at least one dose of study drug</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.07" spread="3.93"/>
                    <measurement group_id="O2" value="38.13" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>11.94</param_value>
            <ci_percent>95.00</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>23.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients &lt;50 Years Old Compared With Metoprolol in Transplant Recipients &gt;/= 50 Years Old.</title>
        <time_frame>Baseline and Month-12</time_frame>
        <population>Nebivolol and metoprolol groups were subdivided into &lt;50 years old and &gt;50 years old subgroups and differences between subgroups were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol &lt;50 Year Old</title>
            <description>Hypertensive kidney transplant recipients less than 50 years of age treated with Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol &gt;/= 50 Year Old</title>
            <description>Hypertensive kidney transplant recipients age 50 years or higher treated with Metoprolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients &lt;50 Years Old Compared With Metoprolol in Transplant Recipients &gt;/= 50 Years Old.</title>
          <population>Nebivolol and metoprolol groups were subdivided into &lt;50 years old and &gt;50 years old subgroups and differences between subgroups were analyzed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.55" spread="14.55"/>
                    <measurement group_id="O2" value="-17.99" spread="13.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>69.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>19.83</dispersion_value>
            <ci_percent>99.7</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.71</ci_lower_limit>
            <ci_upper_limit>126.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients &lt; 50 Years Old Compared With Metoprolol in Transplant Recipients &lt; 50 Years Old</title>
        <time_frame>Change in Baseline, Month-12</time_frame>
        <population>Nebivolol and metoprolol groups were subdivided into &lt;50 years old and &gt;50 years old subgroups and differences between subgroups were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol &lt; 50 Years Old</title>
            <description>Hypertensive kidney transplant recipients less than 50 years of age treated with Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol &lt;50 Years Old</title>
            <description>Hypertensive kidney transplant recipients less than 50 years of age treated with Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients &lt; 50 Years Old Compared With Metoprolol in Transplant Recipients &lt; 50 Years Old</title>
          <population>Nebivolol and metoprolol groups were subdivided into &lt;50 years old and &gt;50 years old subgroups and differences between subgroups were analyzed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.55" spread="14.55"/>
                    <measurement group_id="O2" value="-16.64" spread="12.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>68.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>19.24</dispersion_value>
            <ci_percent>99.17</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.02</ci_lower_limit>
            <ci_upper_limit>123.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percent Change in Plasma Nitric Oxide Level From Baseline to Month-twelve of Treatment With Nebivolol in Transplant Recipients &gt;/= 50 Years Old Compared With Nebivolol in Transplant Recipients &lt; 50 Years Old.</title>
        <time_frame>Change in Baseline, Month-12</time_frame>
        <population>Nebivolol and metoprolol groups were subdivided into &lt;50 years old and &gt;50 years old subgroups and differences between subgroups were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol &gt;/=50 Years Old</title>
            <description>Hypertensive kidney transplant recipients age 50 years or higher treated with Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol &lt;50 Years Old</title>
            <description>Hypertensive kidney transplant recipients age less than 50 years treated with Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Plasma Nitric Oxide Level From Baseline to Month-twelve of Treatment With Nebivolol in Transplant Recipients &gt;/= 50 Years Old Compared With Nebivolol in Transplant Recipients &lt; 50 Years Old.</title>
          <population>Nebivolol and metoprolol groups were subdivided into &lt;50 years old and &gt;50 years old subgroups and differences between subgroups were analyzed.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.25" spread="11.88"/>
                    <measurement group_id="O2" value="-16.64" spread="12.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.32</dispersion_value>
            <ci_percent>99.17</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.25</ci_lower_limit>
            <ci_upper_limit>51.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients &gt;/= 50 Years Old Compared With Metoprolol in Transplant Recipients Age &gt;/= 50 Years Old.</title>
        <time_frame>Change in Baseline, Month-12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol &gt;/=50 Years Old</title>
            <description>Hypertensive kidney transplant recipients age 50 years or higher treated with Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol &gt;/=50 Years Old</title>
            <description>Hypertensive kidney transplant recipients age 50 years or higher treated with Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Plasma Nitric Oxide Level From Baseline to Month-12 of Treatment With Nebivolol in Transplant Recipients &gt;/= 50 Years Old Compared With Metoprolol in Transplant Recipients Age &gt;/= 50 Years Old.</title>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.25" spread="11.88"/>
                    <measurement group_id="O2" value="-17.99" spread="13.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.96</dispersion_value>
            <ci_percent>99.17</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.74</ci_lower_limit>
            <ci_upper_limit>54.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Asymmetric Dimethylarginine (ADMA) Change From Baseline to Month 12 Between the Groups</title>
        <description>Percent change in plasma ADMA (umol/L)=[month-12 plasma ADMA level minus baseline plasma ADMA level] divided by [baseline plasma ADMA level] multiplied by 100, where all levels are in umol/L.</description>
        <time_frame>Baseline, Month-12</time_frame>
        <population>Technical limitations constrained measurements of Asymmetric Dimethylarginine (ADMA), resulting in no analysis for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Asymmetric Dimethylarginine (ADMA) Change From Baseline to Month 12 Between the Groups</title>
          <description>Percent change in plasma ADMA (umol/L)=[month-12 plasma ADMA level minus baseline plasma ADMA level] divided by [baseline plasma ADMA level] multiplied by 100, where all levels are in umol/L.</description>
          <population>Technical limitations constrained measurements of Asymmetric Dimethylarginine (ADMA), resulting in no analysis for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Arginine (ARG) Level Change From Baseline to Month-12 Between Groups</title>
        <description>Percent change in plasma Arginine (umol/L)=[month-12 plasma Arginine level minus baseline plasma Arginine level] divided by [baseline plasma Arginine level] multiplied by 100, where all levels are in umol/L</description>
        <time_frame>Baseline, Month-12</time_frame>
        <population>Technical limitations constrained measurements of plasma Arginine, resulting in no analysis for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol</title>
            <description>Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
          <group group_id="O2">
            <title>Metoprolol</title>
            <description>Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Arginine (ARG) Level Change From Baseline to Month-12 Between Groups</title>
          <description>Percent change in plasma Arginine (umol/L)=[month-12 plasma Arginine level minus baseline plasma Arginine level] divided by [baseline plasma Arginine level] multiplied by 100, where all levels are in umol/L</description>
          <population>Technical limitations constrained measurements of plasma Arginine, resulting in no analysis for this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nebivolol</title>
          <description>Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.
Nebivolol: Nebivolol 5 mg once daily, titrated to a maximum total daily dose of 40 mg to achieve a blood pressure of &lt; 140/ 90.</description>
        </group>
        <group group_id="E2">
          <title>Metoprolol</title>
          <description>Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of &lt;140/90 and continued until month-12 of the study.
Metoprolol: Metoprolol 25 mg twice daily, titrated to a maximum total daily dose of 400 mg to achieve a blood pressure &lt; 140/90.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Herniorraphy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Earache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Influenza-like Illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arm Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Low Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>Small numbers of subjects analyzed in a single center limits precision and generalizability of results.
Technical limitations prevented measurements of asymmetric dimethyl-arginine and arginine leading to absence of analysis for these outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alfonso H. Santos Jr, M,D,</name_or_title>
      <organization>University of Florida</organization>
      <phone>352-273-6374</phone>
      <email>Alfonso.santos@medicine.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

